Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease and Skysona for cerebral adrenoleukodystrophy. The entire gene therapy field is facing tough ...
Its third gene therapy, Lyfgenia (lovotibeglogene autotemcel), is approved for the treatment of sickle cell disease. In a closely competitive race, the therapy secured FDA approval ahead of time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback